Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Ningbo Menovo Pharmaceutical Co., Ltd. on 6ix
Earlier from Ningbo Menovo Pharmaceutical
- Announcement on Not Revising Downward Conversion Price of "Menovo Convertible Bonds"
- Announcement on Resolutions of the 18th Meeting of the 5th Board of Directors
- Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Irbesartan and Hydrochlorothiazide Tablets
- Announcement on Resolutions of the 17th Meeting of the 5th Board of Directors
Later from Ningbo Menovo Pharmaceutical
- Announcement on Self-exercise Results of Reserved and Granted Portion in the 2nd Exercise Period of the 2021 Stock Option Incentive and Restricted Stock Plan and Share Changes
- Announcement on Resolutions of the 20th Meeting of the 5th Board of Directors
- Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Febuxostat Tablets
- Announcement on Resolutions of the 21st Meeting of the 5th Board of Directors
- Announcement on CDE’s Technical Review of the Drug Substance Atorvastatin Calcium by the Holding Subsidiary
Follow Ningbo Menovo Pharmaceutical into a list and get an email when it puts out news.
Follow Ningbo Menovo Pharmaceutical